ResearcherChina Pharmaceutical UniversityNo recent work listed
Shihui Huang
Matched on ORCID iD 0009-0000-5270-2379; OpenAlex author ID A5100708573. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2021: 1 paper · 2022: 2 papers
Papers 3
- Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. Co-author DOI 10.1016/j.ejmech.2022.114116↗
- FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. First author DOI 10.1016/j.phrs.2021.106040↗
- Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01535↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yungen Xu · 3 shared papers, 2021–2022 · strength 0.44
- Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040↗
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
- Shiqi Wu · 3 shared papers, 2021–2022 · strength 0.44
- Paper FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signali… DOI 10.1016/j.phrs.2021.106040↗
- Paper Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. DOI 10.1016/j.ejmech.2022.114116↗
- Paper Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. DOI 10.1021/acs.jmedchem.1c01535↗
- Qin Sun · 2 shared papers, 2021–2022 · strength 0.27
- Shuping Wang · 1 shared paper, 2022 · strength 0.17
- Shuping Wang · 1 shared paper, 2022 · strength 0.15
- Yu Li · 1 shared paper, 2021 · strength 0.12
- Shu-Ping Wang · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.